An LNP-mediated CRISPR/Cas9 system (NTLA-2001 developed by Intellia therapeutics) has been developed to reduce TTR protein levels in the treatment of hATTR amyloidosis with polyneuropathy or transthyretin amyloidosis-related cardiomyopathy (NCT04601051)163,164. This evidence concerns the gene TTR and cardiomyopathy.